Similar articles

• Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.

  Simonsson B. Simonsson B. Leukemia. 1996 Jun;10 Suppl 2:s44-5. Leukemia. 1996. PMID: 8649052 No abstract available.
• Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.

  Rowe JM, Nilsson BI, Simonsson B. Rowe JM, et al. Leuk Lymphoma. 1993 Nov;11(5-6):321-9. doi: 10.3109/10428199309067922. Leuk Lymphoma. 1993. PMID: 7510190 Review.
• [Recent progress in the treatment of hematological malignancies. III. Acute leukemia--bone marrow transplantation].

  Masaoka T. Masaoka T. Nihon Naika Gakkai Zasshi. 1989 Jun;78(6):789-91. Nihon Naika Gakkai Zasshi. 1989. PMID: 2677177 Japanese. No abstract available.
• Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.

  Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A. Martin-Algarra S, et al. Exp Hematol. 1995 Dec;23(14):1503-8. Exp Hematol. 1995. PMID: 8542938
• How do BMTs cure leukaemia? New directions.

  Prentice HG. Prentice HG. Bone Marrow Transplant. 1991;7 Suppl 2:11-3. Bone Marrow Transplant. 1991. PMID: 1878667 Review. No abstract available.